A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT. Journal of Multidisciplinary Sciences and Innovations, [S. l.], v. 5, n. 03, p. 1550–1553, 2026. DOI: 10.55640/. Disponível em: https://ijmri.de/index.php/jmsi/article/view/6541. Acesso em: 22 mar. 2026.